Terms: = Leukemia AND MYCN, N-myc, 4613, ENSG00000134323, NMYC, MODED, ODED AND Treatment
49 results:
1. Inhibition of PRMT5/MEP50 Arginine Methyltransferase Activity Causes Cancer Vulnerability in NDRG2
Ichikawa T; Suekane A; Nakahata S; Iha H; Shimoda K; Murakami T; Morishita K
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38474089
[TBL] [Abstract] [Full Text] [Related]
2. [Clinical characteristics and prognosis of 28 cases of infant acute lymphoblastic leukemia].
Shi Y; Lu Y; Zhang RD; Zhang YY; Lin W; Yu JJ; Wu Y; Fan J; Qi PJ; Huang PL; Cai LX; Huang Q; Zhang P; Sun YM; Liu Y; Zheng HY
Zhonghua Er Ke Za Zhi; 2024 Jan; 62(1):49-54. PubMed ID: 38154977
[No Abstract] [Full Text] [Related]
3. Comparative Analysis of the Embryonal Brain Tumors Based on Their Molecular Features.
Shcherbina V; Kovalevska L; Pedachenko E; Malysheva T; Kashuba E
Discov Med; 2023 Oct; 35(178):733-749. PubMed ID: 37811612
[TBL] [Abstract] [Full Text] [Related]
4. MYCMI-7: A Small MYC-Binding Compound that Inhibits MYC: MAX Interaction and Tumor Growth in a MYC-Dependent Manner.
Castell A; Yan Q; Fawkner K; Bazzar W; Zhang F; Wickström M; Alzrigat M; Franco M; Krona C; Cameron DP; Dyberg C; Olsen TK; Verschut V; Schmidt L; Lim SY; Mahmoud L; Hydbring P; Lehmann S; Baranello L; Nelander S; Johnsen JI; Larsson LG
Cancer Res Commun; 2022 Mar; 2(3):182-201. PubMed ID: 36874405
[TBL] [Abstract] [Full Text] [Related]
5. The biguanide polyamine analog verlindamycin promotes differentiation in neuroblastoma via induction of antizyme.
Urban-Wójciuk Z; Graham A; Barker K; Kwok C; Sbirkov Y; Howell L; Campbell J; Woster PM; Poon E; Petrie K; Chesler L
Cancer Gene Ther; 2022 Jul; 29(7):940-950. PubMed ID: 34522028
[TBL] [Abstract] [Full Text] [Related]
6. Histone deacetylase inhibitor chidamide regulates the Wnt/β-catenin pathway by mycn/DKK3 in B-ALL.
Zhao L; Lv C; Sun L; Li Q; Wang Y; Wu M; Wang Y; Guo Z; Bian S; Kong D; Lin L; Wang Y; Zhou J; Li Y
Invest New Drugs; 2021 Aug; 39(4):961-970. PubMed ID: 33566253
[TBL] [Abstract] [Full Text] [Related]
7. MYC as a target for cancer treatment.
Duffy MJ; O'Grady S; Tang M; Crown J
Cancer Treat Rev; 2021 Mar; 94():102154. PubMed ID: 33524794
[TBL] [Abstract] [Full Text] [Related]
8. Growth inhibition and suppression of the mTOR and Wnt/β-catenin pathways in T-acute lymphoblastic leukemia by rapamycin and mycn depletion.
Kong D; Fan S; Sun L; Chen X; Zhao Y; Zhao L; Guo Z; Li Y
Hematol Oncol; 2021 Apr; 39(2):222-230. PubMed ID: 33300153
[TBL] [Abstract] [Full Text] [Related]
9. Synergistic targeting of CHK1 and mTOR in MYC-driven tumors.
Song X; Wang L; Wang T; Hu J; Wang J; Tu R; Su H; Jiang J; Qing G; Liu H
Carcinogenesis; 2021 Apr; 42(3):448-460. PubMed ID: 33206174
[TBL] [Abstract] [Full Text] [Related]
10. Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells.
Yeh CH; Bellon M; Wang F; Zhang H; Fu L; Nicot C
Mol Cancer; 2020 Sep; 19(1):139. PubMed ID: 32907612
[TBL] [Abstract] [Full Text] [Related]
11. Steroid receptor-associated and regulated protein is a biomarker in predicting the clinical outcome and treatment response in malignancies.
Naderi A
Cancer Rep (Hoboken); 2020 Oct; 3(5):e1267. PubMed ID: 32706923
[TBL] [Abstract] [Full Text] [Related]
12. Diosgenin as a Novel Alternative Therapy for Inhibition of Growth, Invasion, and Angiogenesis Abilities of Different Glioblastoma Cell Lines.
Khathayer F; Ray SK
Neurochem Res; 2020 Oct; 45(10):2336-2351. PubMed ID: 32683533
[TBL] [Abstract] [Full Text] [Related]
13. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
Wang NY; Xu Y; Xiao KJ; Zuo WQ; Zhu YX; Hu R; Wang WL; Shi YJ; Yu LT; Liu ZH
Eur J Med Chem; 2020 Apr; 191():112152. PubMed ID: 32088495
[TBL] [Abstract] [Full Text] [Related]
14. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting mycn in neuroblastoma.
Chava S; Reynolds CP; Pathania AS; Gorantla S; Poluektova LY; Coulter DW; Gupta SC; Pandey MK; Challagundla KB
Mol Oncol; 2020 Jan; 14(1):180-196. PubMed ID: 31637848
[TBL] [Abstract] [Full Text] [Related]
15. Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells.
Sheng Y; Ji Z; Zhao H; Wang J; Cheng C; Xu W; Wang X; He Y; Liu K; Li L; Voeltzel T; Maguer-Satta V; Gao WQ; Zhu HH
Cell Prolif; 2019 Jul; 52(4):e12611. PubMed ID: 31054182
[TBL] [Abstract] [Full Text] [Related]
16. The small molecule Bcl-2/Mcl-1 inhibitor TW-37 shows single-agent cytotoxicity in neuroblastoma cell lines.
Klenke S; Akdeli N; Stelmach P; Heukamp L; Schulte JH; Bachmann HS
BMC Cancer; 2019 Mar; 19(1):243. PubMed ID: 30885150
[TBL] [Abstract] [Full Text] [Related]
17. Long-term analysis of children with metastatic neuroblastoma treated in the ENSG5 randomised clinical trial.
Moreno L; Vaidya SJ; Schrey D; Pinkerton CR; Lewis IJ; Kearns PR; Machin D; Pearson ADJ;
Pediatr Blood Cancer; 2019 Apr; 66(4):e27565. PubMed ID: 30516328
[TBL] [Abstract] [Full Text] [Related]
18. Chemotherapy-induced niche perturbs hematopoietic reconstitution in B-cell acute lymphoblastic leukemia.
Tang C; Li MH; Chen YL; Sun HY; Liu SL; Zheng WW; Zhang MY; Li H; Fu W; Zhang WJ; Liang AB; Tang ZH; Hong DL; Zhou BS; Duan CW
J Exp Clin Cancer Res; 2018 Aug; 37(1):204. PubMed ID: 30157922
[TBL] [Abstract] [Full Text] [Related]
19. mycn is a novel oncogenic target in adult B-ALL that activates the Wnt/β-catenin pathway by suppressing DKK3.
Kong D; Zhao L; Sun L; Fan S; Li H; Zhao Y; Guo Z; Lin L; Cui L; Wang K; Chen W; Zhang Y; Zhou J; Li Y
J Cell Mol Med; 2018 Jul; 22(7):3627-3637. PubMed ID: 29673070
[TBL] [Abstract] [Full Text] [Related]
20. The Expanding World of n-myc-Driven Tumors.
Rickman DS; Schulte JH; Eilers M
Cancer Discov; 2018 Feb; 8(2):150-163. PubMed ID: 29358508
[TBL] [Abstract] [Full Text] [Related]
[Next]